Kornimate/medical-research-clean huggingface dataset:
gluten free diet in preventing graft versus host disease in patients undergoing donor stem cell transplant

Conditions: Graft Versus Host Disease; Hematopoietic Cell Transplantation Recipient

Summary: this pilot clinical trial studies how well a gluten free diet works in preventing graft versus host disease in patients who are undergoing a donor stem cell transplant. sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft versus host disease). a gluten free diet may decrease intestinal inflammation and graft versus host disease in patients who are undergoing a donor stem cell transplant.

primary objectives: i. to determine the rate and severity of gastrointestinal (gi) graft versus host disease (gvhd) in patients assigned to, and compliant with, a gluten free diet (gfd) during initial transplant hospitalization. secondary objectives: i. to determine the tolerance of, and compliance with, a gfd in patients undergoing allogeneic hematopoietic stem cell transplant (allo-sct). outline: patients undergo a gluten free diet for 30 days during initial hospitalization for allo-sct, from the time of admission to discharge. after completion of study, patients are followed up at 1, 3, 6, and 12 months.

Eligibility criteria:
inclusion criteria: * patient undergoing an allo-sct * no history of celiac disease or non-celiac gluten sensitivity * male and female and all ethnic groups are eligible exclusion criteria: * pregnant women * children are not eligible as the transplant program is certified as an adult only transplant program
genetic of sports induced endofibrotic remodeling

Conditions: Genetic Syndrome

Summary: search for a genetic cause of vascular endofibrose

perform a dna analysis to mark the existence of mutations in one or more genes encoding proteins involved in vascular remodeling high. 5 patients or relatives of patients topics

Eligibility criteria:
inclusion criteria: * high level reached cyclists vascular endofibrose * cyclist high level and not sick with a brother or sister is senior cyclist reaches the vascular endofibrose. exclusion criteria: * not obtaining consent
knowledge of pregnant women concerning pertussis, vaccination against pertussis and cocooning strategy

Conditions: Pertussis

Summary: in france, it has been recommended since 2022 that pregnant women be vaccinated against pertussis from 20 to 36 weeks' gestation. this vaccination schedule is inspired by the anglo-saxon model and studies showing the effectiveness of this practice. the aim of this vaccine is to protect the newborn by transferring antibodies from the fetus to the placenta, because pertussis is a particularly serious disease in newborns.

the aim is to describe pregnant women's knowledge concerning pertussis, vaccination against pertussis during pregnancy and the cocooning strategy.

Eligibility criteria:
inclusion criteria: * pregnant between 20 and 41 weeks of amenorrhea * primiparous * aged more than 18 * agreed to participate in the study exclusion criteria: * multiparous * protected by law (guardianship, guardianship, safeguarding of justice) * not agreed to participate in this study

Keywords: cocooning strategy pertussis pregnancy vaccination against pertussis
b-dependant rare autoimmune diseases - cohort of patients with suspected diagnosis of primitive sjögren syndrome

Conditions: Sjogren's Syndrome

Summary: the objectif is to study the diagnosis performance of the different classification criteria in reference to the gold standard consisting of the diagnosis made by expert doctors after standardized assessment, of pss (primary sjogren syndrome)

the formation of this patient is single-center prospective intervention. it consists of collecting data from patients suspected of pss from standardized biological clinical data and imaging examination and additional pathology. * sjögren patients will be followed at inclusion, 2y, 3y, 4y, 6y, 8y and 10 years. blood, fluid, sells and urine samples will be collected at inclusion, 4y et 10y. * non-sjögren controls will be followed at inclusion and 4y and samples will be collected at the same visits.

Eligibility criteria:
inclusion criteria: * major patient * suspicion of ssp (clinical or biological criteria, i.e. dry eye or oral syndrome, arthritis, parotidomegaly, neuropathy, kidney or lung disease...) * patient affiliated with social security * patient who has signed written informed consent exclusion criteria: * refusal to participate * pregnant and lactating woman
a trial of mbc-11 in patients with cibd

Conditions: Bone Metastasis

Summary: this study evaluates mbc-11 (a conjugate of a bone-targeting vehicle (etidronate) and a cytostatic agent \[ara-c\] in patients with malignant tumors with cibd. this is a first use in human.

a standard "3+3" dose escalation design to determine maximum tolerated dose with consecutive different dose level cohort recruitment. the following dose levels to be investigated: 0.5 mg/kg, 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, 10 mg/kgm 20 mg/kg. the study for each patient consists of 14-days screening period, single dose administration of mbc-11 followed by 7-day safety monitoring and then 2 cycles of multiple use of mbc-11 (28 days each cycle, study drug is administered at days1-5). in case of partial metabolic reaction/stable metabolic reaction therapy maybe prolonged up to 4 cycles (at investigator and sponsor consideration)

Eligibility criteria:
inclusion criteria: * histologically confirmed malignant tumor (breast cancer, prostate cancer etc) * bone metastases, documented by radiographs, bone scan * no available standard chemotherapy or no indication for chemotherapy at the time of screening * eastern cooperative oncology group \[ecog\] status 0-2 * adequate bone marrow function (hemoglobin ≥ 9 g/dl with or without transfusion requirement, absolute neutrophil count ≥ 1500/mm3, and platelets ≥ 75,000/mm3) * adequate liver function (bilirubin ≤ 2 x upper limit of normal \[uln\], alanine aminotransferase \[alt\] ≤ 2.5 x uln). * adequate renal function (creatinine ≤ 1.5 x uln) and creatinine clearance ≥ 50 ml/min \[measured or calculated by nomogram\]). exclusion criteria: * systemic chemotherapy and/or investigational therapy within the previous 4 weeks * fracture ≤ 6 month prior the inclusion in the study * brain metastasis * serum calcium levels \< 8.5 mg/dl (\< 2.2 mmol/l)
preventing anxiety and depression in older hispanics

Conditions: Depression; Anxiety

Summary: the purpose of this study is to look at the best ways to prevent anxiety and depression in older latino adults who are at risk for developing anxiety and depression. participants will be randomized to either a health promotion intervention or a healthy lifestyles education program.

given the prevalence and morbidity of depression in later life, the inadequacies of current treatment approaches for averting years living with disability, the inequities in access to the mental health care delivery system, and the workforce shortages to meet the mental health needs of older latinos, development and testing of innovative strategies to prevent depression and anxiety are of great public health significance and have the potential to change practice.

Eligibility criteria:
inclusion criteria: * latino (self-identified); * age 60+; * subthreshold depression defined as a score ≥ 5 on the patient health questionnaire (phq-9), or subthreshold anxiety as defined as a score ≥ 5 on the gad-7; * do not meet criteria for current mdd or gad as indicated by the mini international neuropsychiatric inventory (mini); * voluntary informed consent for participation in the study by the participant or by the participant's legally designated guardian or conservator; * medical clearance for participation in a health promotion intervention by a physician, physician's assistant, or nurse practitioner; * not taking steroidal or anti-inflammatory medication (including nsaids) within 2 weeks of treatment randomization; * expect to be resident in miami for the subsequent 2 years. exclusion criteria: * have met criteria for major depressive disorder or generalized anxiety disorder within the past 12 months; * have met criteria for alcohol or other substance abuse disorders within the past 12 months; * are currently receiving antidepressant medication or participating in other mental health treatment; * have a lifetime history of bipolar disorder or other psychotic disorder including major depression with psychotic features; * have a diagnosis of any neurodegenerative disorder or dementia (parkinson's disease, alzheimer's, vascular, frontotemporal dementia, etc.) or significant cognitive impairment as indicated by a mini mental status exam (mmse) score \<24; * are current tobacco smokers since smoking influences systemic inflammation; * have contraindications to physical activity outlined in the american college of sports medicine standards; * have high suicide risk, i.e., intent or plan to attempt suicide in the near future (a response of "yes" to questions 3, 4, and/or 5 on the paykel questionnaire; * are unable to complete 10 m walk test; * currently residing in a nursing or group home; * have a terminal physical illness expected to result in the death within one year; * any evidence of current infection; and * have an acute or severe medical illness that precludes them from safely participating in a health promotion intervention (further defined in the protocol).
mglur5 imaging in als using pet

Conditions: Amyotrophic Lateral Sclerosis

Summary: in als models, it was shown that receptors, that bind an important messenger substance (glutamate) in the brain, are increased. in this research project, the investigators want to use a specific radioactive substance to find out whether these receptors are more detectable in people with als than in healthy people and increase over the course of the disease.

with this study, the investigators want to examine whether receptors (docking points on the surface of a nerve cell) that bind an important messenger substance in the brain (glutamate) are increased in patients with amyotrophic lateral sclerosis (als) as the disease progresses. based on observations from als models, the investigators suspect that this increase in receptors contributes to the damage to the nerve cells in als. to image these receptors, the investigators use a specific radioactive substance and imaging combining positron emission tomography (pet), magnetic resonance spectroscopy (mrs) and magnetic resonance imaging (mri) of the brain and spinal cord. the investigators will examine healthy people and als patients. the reason is that little is known about the receptor, even in healthy people. the investigators also do not know if and when the receptor is increasingly detectable in the course of the als disease. only by comparing diseased and healthy people it can be determined if and when the receptor is built up in als patients. the investigators also hope to gain more information, e.g. about the distribution of receptors in the brain of healthy people compared to patients.

Eligibility criteria:
inclusion criteria: * clinically probable, probable laboratory supported, or definite als according to the revised version of the el escorial world federation of neurology criteria (eec) (45) * disease duration ≤18 months * pre-study alsfrs-r progression between disease onset and screening of - 0.4 points/month or worse (calculated by alsfrs -r total score decline form 48 divided by the months since onset of als symptoms) * upright slow vital capacity (svc) ≥65 % of normal (best of three measurements) exclusion criteria : * previous participation in another clinical study involving trial medication within the preceding 12 weeks * history or presence of significant psychiatric disease, such as depression, evaluated with the als depression questionnaire (adi-12) ≥ 23 (43) since depression has an impact on mglur5 expression (44) * use of tobacco, including cigarettes, smokeless tobacco, cigars, and pipes; ex- smoker having quit smoking ≥ 2 years

Keywords: receptor, metabotropic glutamate 5 brain / diagnostic imaging positron-emission tomography / methods radiopharmaceuticals / pharmacokinetics* pss232 humans adult
dextromethorphan effect on central sensitization to pain in healthy volunteers

Conditions: Experimental Pain; Hyperalgesia

Summary: the aim of this study is to assess the anti-hyperalgesic effect of dextromethorphan in healthy volunteers compared to placebo.

this is a cross-over group, double-blind, randomized clinical trial in healthy volunteers comparing dextromethorphan and inactive control on freeze-induced hyperalgesia, experimental pain, diffuse noxious inhibitory control (dnic), pupillary reaction and reaction time. the influence of cyp3a4 and mdr1 polymorphism on the dextromethorphan analgesic efficacy will be measured. the study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo). each study sequence consists of 3 assessment days (day -1, day 0 = first treatment administration and day 1).

Eligibility criteria:
inclusion criteria: * healthy male volunteers * aged between 18 and 45 years * cyp2d6 extensive and intermediate metabolizers * body mass index (bmi) between 19 and 30 kg/m2 * systolic blood pressure between 100 and 150 mmhg, diastolic blood pressure between 50 and 90 mmhg, heart rate between 45 and 90 beats per minute * without treatment during the 7 days before inclusion specially no use of analgesic and anti-inflammatory drugs * cooperation and understanding enough to conform to the study obligations * having given free informed written consent * affiliated to the french social security * inscription or acceptation of inscription in the national register of volunteers involved in trials. exclusion criteria: * hypersensitivity to the active substance or to any of the excipients * lactose intolerance * hypertension * history of stroke * severe heart failure * severe hepatic impairment * shortness of breath * congenital galactosemia, glucose-galactose malabsorption, lactase deficiency * association with linezolid * pre-existence or history of peripheral neuropathy due to a cause different from neurotoxic chemotherapy * diabetes (type i and ii) * cyp2d6 poor and ultra-rapid metabolizers * ast, alt, total bilirubin twice the average * dextromethorphan intake during the 7 days before inclusion * medical and surgical history incompatible with the study * disease progression during inclusion * excessive consumption of alcohol (\> 50g/day), tobacco (≥ 10 cigarettes/day), coffee, tea or drinks with caffeine (equivalent to more than 4 cups a day) or any addiction to drugs * subject lacking concentration during tests training and low test results reproducibility * subject does not meet the selection criteria for its ability to discriminate sensations to noxious stimuli during psychometric tests * subject exclusion period, or the total allowable compensation exceeded * subject undergoing a measure of legal protection (guardianship, supervision

Keywords: antinociception freeze-induced hyperalgesia model dextromethorphan nmda-receptors pharmacogenetic cyp3a4 gene mdr1 gene
early diagnosis of anoxic brain injury for resuscitated patients

Conditions: Cardiac Arrest

Summary: sudden cardiac arrest (ca) in adults remains a major public health issue in industrialized countries, leading to a mortality rate greater than 90%. the analysis of french data estimates the number of sudden deaths at around 40,000 per year. the incidence rate for non-hospital cas is 55 per 100,000 every year with an immediate survival rate of 9% and 4.8% at one year.

approximately 80 % of patients who survive ca with cardiopulmonary resuscitation are comatose. the longer it lasts, the lower chances of recovery. the evaluation of the neurological prognosis of these patients is an important issue. indeed, 72% of patients admitted to an intensive care unit after resuscitation from ca will give rise to an ethical discussion with the family. the prognostication strategy is usually based on a multimodal process involving clinical examination, electro-neurophysiological and biological examinations. we plan to study the relevance of early neurological prognostic tests in the aftermath of ca and in particular the most recent techniques such as the use of a clinical score (cahp for cardiac arrest hospital prognosis), automated infrared pupillometry (neurolight algiscan, idmed) for pupillary reflex measurement and quantitative analysis of the continuous amplitude-integrated electroencephalogram (aeeg) brain quick icu line, micromed. these new prognostic criteria for ca (cahp score, pupillometry and aeeg) developed separately have not yet been integrated into a multimodal strategy. the goal of this study is to evaluate the performance of cahp score, infrared automated pupillometry and aeeg to predict as early as 24h from rosc the neurological prognosis (cerebral performance categories) at hospital discharge.

Eligibility criteria:
inclusion criteria: * admission in intensive care unit (icu) following cardiac arrest with rosc exclusion criteria: * minor patient * cardiac arrest (ca) occuring in icu * decision before icu admission to withdraw life-sustaining treatments * patient with post-rosc glasgow coma score = 15

Keywords: cardiac arrest coma hypoxic brain damage prognosis neurological examination pupillary reflex electroencephalography targeted temperature management biomarkers clinical score evoked potentials
a clinical trial on the efficacy of gastric probiotics in the treatment of helicobacter pylori infection

Conditions: Helicobacter Pylori Infection

Summary: the purpose of this study is to assess the safety and efficacy of lactobacillus plantarum, bacillus coagulans and lactobacillus plantarum + bacillus coagulans for eradication of helicobacter pylori, as well as the efficacy of lactobacillus plantarum and bacillus coagulans on side-effect caused by helicobacter pylori.

all patients included in this randomized controlled clinical trial will be selected according to strict inclusion and exclusion criteria. at the same time, the benefits and risks of participating in this trial will be explained to the patients before the start of the study, the patients' right to informed consent will be respected, and the informed consent will be signed. after being informed about the study and potential risks, all patients giving written informed consent will undergo a screening period to determine eligibility for study entry. at week 0, patients who meet the eligibility requirements will be randomized in a double-blind manner (participants and investigator) in a 1:1:1:1 ratio to lactobacillus plantarum (1.5×10\^10 per time, three times daily) or bacillus coagulans (1.5×10\^10 per time, three times daily) or lactobacillus plantarum + bacillus coagulans (1.5×10\^10 per time, three times daily) or placebo ( 15g per time, three times daily). at the same time, volunteers will be recruited from healthy people to perform the same treatment.

Eligibility criteria:
inclusion criteria: * aged 18-75 years. * diagnosed by 13c-ubt within 2 weeks before entry. exclusion criteria: * previous treatment for h. pylori infection. * administration of antibiotics, probiotics/prebiotics, ppis, h2 receptor antagonists, bismuth preparations, laxatives, anti-diarrhoeals, and certain antimicrobial traditional chinese medicines 4 weeks before. * previous history of gastrointestinal surgery. * severe or unstable diseases. * pregnancy or lactation. * alcoholics and drug abusers. * staff of this trial.

Keywords: gastric probiotics side-effect eradication rate helicobacter pylori
anticoagulation in af ablation and effects on neurocognitive function

Conditions: Atrial Fibrillation; Cerebrothromboembolus; Neurocognitive Function

Summary: atrial fibrillation (af) is the most common cardiac arrhythmia in the united states, and treatment by af ablation is quickly becoming the favored definitive therapy. nonetheless, af ablation comes with some risk, including bleeds related to vascular access and myocardial damage, as well as the rare incidence of clinical stroke from blood clots that travel from the heart to the brain, termed "cerebrothromboemboli." in fact, cerebrothromboemboli without any symptoms have been detected by special imaging procedures called brain magnetic resonance imaging (mri) in as many as 22% of cases.(1-6) there remains clinical equipoise amongst experts regarding balancing the risks and benefits of continued versus interrupted blood thinning, or "anticoagulation" during af ablation as they pertain to risk of bleed and cerebrothromboemboli prevention, respectively, and the potentially more subtle sequelae of these apparently silent cerebrothromboemboli remain unknown. in fact, both interruption and continuation of anticoagulation during af ablation are the standard of care. the investigators will perform the first randomized trial of uninterrupted versus interrupted anticoagulation in patients undergoing af ablation to determine if it mitigates neurologic injury. the objective of this research is to investigate the effect of continued anticoagulation for af ablation on cerebrothromboemboli, and the neurocognitive sequelae of embolic lesions, which to this point are considered subclinical. the investigators hypothesize that continued anticoagulation will both reduce cerebrothromboemboli and mitigate any potential decline in neurocognitive function post-procedurally. the investigators also hypothesize that the incidence of cerebrothromboemboli (cte) by mri will mediate that difference.


Eligibility criteria:
inclusion criteria: * patients 18 years old and older with af (paroxysmal or persistent) who are to undergo an elective af ablation procedure at ucsf will be eligible for enrollment. exclusion criteria: * patients will be excluded if they have: * a contraindication of warfarin therapy (pregnancy, recent bleed, inability of have serial inr checks) * a contraindication or relative contraindication to interruption of anticoagulation (e.g. mechanical valve, clotting disorder such as antiphospholipid syndrome, recent history of pulmonary embolism or history of recurrent pulmonary embolism) * a contraindication to transesophageal echocardiogram; any contraindication to mri * have a diagnosed condition of dementia or a diagnosis that precludes accurate assessment of neurocognitive function * non-english speakers * inability to give informed consent.

Keywords: atrial fibrillation ablation cerebrothromboemboli neurocognitive function